Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

amolimogene bepiplasmid

A plasmid DNA-based vaccine consisting of small biodegradable poly(lactide-co-glicolide) polymer microparticles encapsulating plasmid-DNA vector encoding a chimeric protein comprising epitopes derived from the E6 and E7 oncoproteins of the human papillomavirus (HPV) types 16 and 18, with potential antineoplastic activity. Upon intramuscular vaccination, amolimogene bepiplasmid may elicit the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells positive for HPV-16 and -18 E6 and E7 and may result in a reduction in tumor cell growth. HPV types 16 and 18 oncoproteins E6 and E7 are most commonly involved in cervical cancer.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:amolimogene
bacterially derived DNA and microparticles made of poly(D,L-lactide-co-glydolide)
DNA (synthetic plasmid p3kDRalphaHPV16-18)
Code name:ZYC101a
Chemical structure:bacterially derived DNA and microparticles made of poly(D,L-lactide-co- glydolide)
DNA (synthetic plasmid p3kDRαHPV16-18)
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search